Bionic ETF

ISIN: IE0005TF96I9

  • Invest in the companies driving bionic engineering
  • Profit from a fast evolution
  • Growing demand from a fast-aging global population
  • A way to make a diversified investment
  • HighTech-Medicine that positively impacts people and our planet

Risks of a Bionic ETF: You may lose money up to the total loss of your investment due to the Main Risk Factors, such as Industry or Sector Concentration Risk and Liquidity Risks described below in the KID and the sales prospectus. Evolving of the market is not guaranteed.

What is Bionic?

Bionic is a portmanteau from biology and electronics and is often confused with the word “Cyborg,” which describes a being with organic and mechatronic body parts. Bionics, or biologically inspired engineering, is the application of concepts and systems found in nature to design systems and products. With advancements in physiotherapy, robotics and medicine, bionic engineering is poised to find applications in healthcare.

Source: Wikipedia.

Why Invest in a Bionic ETF?

Bionics is a fast-expanding medical field set to fulfill a substantial need. Our Bionic ETF offers one of the few ways to invest in a diversified portfolio of companies.

Helping the Ageing Population

Source: UN population prospects.

Experts anticipate there are four stages to the biomachine interface evolution.1 Below are some examples:

1 Source: McKinsey Global Institute.

Companies in this ETF

Today the companies underlying the Bionic ETF specialize in a range of fields, from heart valves to medical implants and diabetes monitoring devices. They include Edwards Lifesciences, a leader in artificial heart valves; Medtronic, which makes insulin pumps and pacemakers; and Stryker Corp, known for its joint replacements. As the new interfaces between man and machine evolve, so will the ETF’s holdings.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader in diabetes care technology. Dexcom simplifies and improves diabetes management around the world.

VanEck Bionic Engineering UCITS ETF

ISIN: IE0005TF96I9

  • Bionic ETF invests in global leaders in healthcare trends
  • Companies involved in groundbreaking healthcare technology solutions for the most complex and challenging conditions
  • An impact ETF
  • 0.55% total expense ratio

Risk indication: 6 out of 7

Lower risk: Typically lower reward

Higher risk: Typically higher reward

Main Risk Factors of Bionic ETF


It exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price or at all.

For more information on risks, please see the “Risk Factors” section of the relevant Fund’s prospectus, available on

Discover more ETFs

More ETFs

Why Invest in VanEck ETFs?

  • Since we were founded in 1955 we have constantly been at the forefront of innovation, giving you access to new opportunities like gold funds, emerging market funds and ETFs.
  • We are privately-held, allowing us to focus on our clients’ long-term interests.
  • Our ETFs are transparent: they acquire the underlying securities (no synthetic replication). Securities are not lent out.*
* This only holds for VanEck’s European ETFs.
Please contact us for more information: